Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rocket Pharmaceuticals, Inc. (RCKT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, late-stage biotechnology company, Rocket uses SEC reports to communicate material information about its gene therapy pipeline, financial condition, governance and significant corporate events.
Investors can use this page to locate current reports on Form 8-K, which Rocket files to describe events such as financial results, strategic corporate reorganization and pipeline prioritization, clinical trial developments and regulatory milestones. Recent 8-K filings referenced in available information include announcements of quarterly financial results, FDA acceptance of the resubmitted Biologics License Application (BLA) for KRESLADI in severe leukocyte adhesion deficiency-I (LAD-I), lifting of the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease, and leadership or board changes.
In addition to 8-Ks, users can access Rocket’s periodic reports on Forms 10-K and 10-Q, which provide more detailed discussions of its AAV and lentiviral gene therapy programs, risk factors and financial statements. These filings help explain how Rocket is prioritizing its AAV cardiovascular platform—covering Danon disease, PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy—while advancing regulatory activities for KRESLADI and pausing additional internal investment in certain other programs.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as clinical and regulatory updates, restructuring plans, and changes in executive leadership. Real-time EDGAR updates allow users to see new Rocket filings as they are posted, while Form 4 insider transaction data and proxy materials can be reviewed to understand equity awards, inducement grants and governance practices. This page serves as a focused entry point for analyzing how Rocket’s SEC disclosures relate to the development and potential commercialization of its rare disease gene therapy portfolio.
Rocket Pharmaceuticals (RCKT) announced FDA acceptance of its resubmitted BLA for KRESLADI (marne‑cel), an investigational lentiviral gene therapy for severe Leukocyte Adhesion Deficiency‑I (LAD‑I). The agency set a PDUFA date of March 28, 2026, establishing the formal timeline for a U.S. approval decision.
KRESLADI targets a rare, life‑threatening immune disorder that often proves fatal in childhood without allogeneic stem cell transplant. If approved, the company is eligible for a Rare Pediatric Disease Priority Review Voucher, which can carry strategic value for future regulatory filings. The company attached a press release (Exhibit 99.1) and cautioned that approval is not assured, consistent with forward‑looking statement disclosures.
Insider equity awards and option grants were recorded for Rocket Pharmaceuticals (RCKT). The reporting person, the company’s Chief Medical Officer, was issued 283,018 restricted stock units (RSUs) that convert one-for-one to common shares and an additional 62,893 RSUs, for a total beneficial ownership of 345,911 shares after the transactions. The filing also shows a grant of 383,854 non-qualified stock options exercisable at
Vesting schedules are time-based: one-third of the larger RSU and option awards vest on
Peter Fong, a director of Rocket Pharmaceuticals, Inc. (RCKT), reported equity awards on a Form 4 filed for transactions dated 09/24/2025. The filing shows two grants of restricted stock units (RSUs): 23,333 RSUs that convert one-for-one to common stock and vest in full on 09/24/2026, and 30,000 RSUs that begin vesting monthly over a three-year period following 09/23/2025. Both grants are recorded with a reported price of $0, indicating they were awards rather than open-market purchases. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing discloses current beneficial ownership totals of 23,333 and 53,333 shares following the respective transactions.
Rocket Pharmaceuticals (RCKT) director Peter Fong filed a Form 3, the initial statement of beneficial ownership. The filing states that no securities are beneficially owned. The reported event date is 09/24/2025, and the form was signed by attorney-in-fact John Militello.
This is a routine Section 16 compliance filing that establishes the insider’s baseline ownership at the time of becoming a reporting person.
Rocket Pharmaceuticals reported a board change. Director Pedro Granadillo resigned from the Board of Directors, effective September 30, 2025. The company stated that his decision did not involve any disagreement on matters related to operations, policies, or practices.
Rocket Pharmaceuticals, Inc. announced it voluntarily withdrew its U.S. Biologics License Application for mozafancogene autotemcel (RP-L102 / Fanskya) on October 3, 2025. The company stopped new internal investment in RP-L102 in July 2025 and also withdrew its MAA with the EMA in July 2025, citing a corporate prioritization to focus resources on programs with clearer regulatory and commercial paths. Rocket said the withdrawal reflects business and strategic considerations and does not reflect safety or efficacy concerns; it stated that data to date show RP-L102 has been generally well tolerated with no significant safety signals. The company will consider external partnerships and reserves the ability to re-engage regulators later if a sustainable pathway emerges.
Rocket Pharmaceuticals, Inc. (RCKT) disclosed the appointment of Dr. Fong to its board of directors in a current report. The filing states there are no arrangements or understandings between Dr. Fong and any other person regarding the appointment, no family relationships between Dr. Fong and company officers or directors, and no related person transactions as defined under Regulation S-K. The notice is brief and limited to governance disclosures; it confirms the director addition and the absence of conflicts or reportable transactions, giving investors a clear, administrative update on the board composition and compliance with related‑party disclosure rules.
RTW Investments, LP and Roderick Wong, M.D. filed a Form 4 reporting settlement of multiple equity swaps and related transactions in Rocket Pharmaceuticals (RCKT). On 09/19/2025 three previously disclosed equity swaps expired and settled, resulting in the conversion/settlement of positions tied to 1,000,000, 41,000, and 59,000 shares at specified reference prices. The Form shows simultaneous acquisitions and dispositions tied to those settlements but states the aggregate beneficial ownership did not change after settlement. The filing also discloses 47,667 restricted stock units held by Dr. Wong that convert one-for-one to common stock and will vest in full on June 18, 2026. The Adviser and Dr. Wong disclaim beneficial ownership except to the extent of any pecuniary interest.
Rocket Pharmaceuticals, Inc. (RCKT) Form 3 reports an initial Section 16 filing for Syed Ali-aamir Rizvi. The filing identifies Mr. Rizvi as Chief Medical Officer and provides his business address at Rocket Pharmaceuticals' Cranbury, NJ location. The event date triggering the filing is 09/15/2025, and the form states no securities are beneficially owned by the reporting person at this time. The document is signed by an attorney-in-fact on behalf of Mr. Rizvi on 09/22/2025.
Rocket Pharmaceuticals announced the separation of Dr. Kinnari Patel and related consulting arrangements. Under a Separation and Release Agreement dated September 11, 2025, Dr. Patel will receive her salary and benefits through December 31, 2025, payment for accrued unused paid time off, a lump sum severance payment of $482,040 conditioned on signing a release within seven days, and a lump sum healthcare allowance of $30,045 to cover approximately ten months of COBRA premiums. Concurrently, the company entered a Consulting Agreement effective after the release revocation period and continuing through December 31, 2026, under which Dr. Patel will provide general consulting services for an aggregate retainer of $582,156. The Consulting Agreement preserves her restricted stock units and options during the consulting period. The Separation and Consulting Agreements are filed as Exhibits 10.1 and 10.2 and are incorporated by reference.